Visual Science

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
Thursday, March 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of Inaugural ROP Awareness Week, Feb. 26 - March 3, 2024

Retrieved on: 
Wednesday, February 21, 2024
Education, Medical director, Medical statistics, Parent, Infant, Pregnancy, University, Organization, Retinopathy, Diagnosis, Gestational age, Head, Social media, Section, Mental health, MBA, Associate professor, MSC, Initiative, Doctor of Psychology, Distribution, Partnership, FACS, National Eye Institute, Ear, University of Illinois Urbana-Champaign, Paratriathlon, ROP, Visual impairment, Safety, Division, MD, Visual Science, Diversity, Patient, Nursing

CHICAGO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has launched the new "Retinopathy of Prematurity Education and Support Program," as part of its first ROP Awareness Week, declared Feb. 26 – March 3, 2024. The group is offering a variety of free educational resources to the public and professionals, including fact sheets, social media graphics in English and Spanish, dedicated online resources, and a new video series.

Key Points: 
  • "Diagnosing and treating ROP early is essential for preventing or lessening ROP-associated vision loss," said Jeff Todd, president and CEO of Prevent Blindness.
  • To help address the need for ROP awareness and education, Prevent Blindness convened leading organizations in the parent support, education, and advocacy arenas to partner on creating the ROP Education and Support Program.
  • The ROP Education and Support Program and ROP Awareness Week is supported by funding from Regeneron .
  • In the Prevent Blindness Focus on Eye Health Expert Series, " Retinopathy of Prematurity ," Jeff Todd, president and CEO of Prevent Blindness, interviews R.V.

ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

Retrieved on: 
Tuesday, January 23, 2024
ANN, Patient, Therapy, RRD, Clinical trial, University, ONL, Safety, Visual Science, Retina, Club, Pharmaceutical industry

ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Zacks, M.D., Ph.D., chief scientific officer and co-founder of ONL Therapeutics, and the Edna H. Perkiss Research Professor of Ophthalmology and Visual Sciences at the Kellogg Eye Center of the University of Michigan, will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment (RRD) at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.

Key Points: 
  • ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Zacks, M.D., Ph.D., chief scientific officer and co-founder of ONL Therapeutics, and the Edna H. Perkiss Research Professor of Ophthalmology and Visual Sciences at the Kellogg Eye Center of the University of Michigan, will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment (RRD) at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.
  • “We believe our Phase 2 randomized study to assess the safety and efficacy of intravitreal ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD) could play an important role in treating this vision-threatening condition, and we look forward to sharing an update at the Macula Society meeting,” said David Esposito, chief executive officer of ONL Therapeutics.
  • “With the study now fully enrolled we will focus our attention on gathering and analyzing the data with a goal to share topline results in the second quarter of 2024.”
    Details of the podium presentation are as follows:
    Fas Inhibition with ONL1204 for Macula-off Rhegmatogenous Retinal Detachment (RRD): Study Population Data on a Phase 2, Multicenter, Randomized, Sham-controlled, Single-Masked, Clinical Trial
    Edna H. Perkiss Research Professor of Ophthalmology and Visual Sciences, Kellogg Eye Center

ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Genetics, Science, Research, Therapy, Disease, Animation, Protein, Cytoplasm, Multimedia, Inflammation, Biochemistry, Autoimmune disease, Visual Science, Genome, RT, ORF2, 3D, Cancer, Autoimmunity, Pharmaceutical industry, Vaccine, Nature

ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase (RT).

Key Points: 
  • ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase (RT).
  • The supporting research was co-led by ROME as part of a significant collaboration with more than a dozen leading academic groups and industry organizations.
  • View the full release here: https://www.businesswire.com/news/home/20231214251491/en/
    LINE-1 reverse transcriptase (orange) can produce RNA-DNA hybrids in the cytoplasm, a new study finds.
  • These aberrant products can trigger inflammation, and might explain how LINE-1 contributes to autoimmune disease and other disease biology.

Hexiris Pharma Welcomes World-Renowned Ophthalmologist Dr. Ike Ahmed to its Scientific Committee

Retrieved on: 
Monday, October 30, 2023
Knowledge, American Academy of Ophthalmology, FDA, Research, AGS, American Glaucoma Society, Vision, Slit lamp, ASCRS, Refractive surgery, ISGS, Glaucoma, MIGS, Pressure, MD, University of Utah, AAO, Glaucoma surgery, Alan, University, COS, Cataract, Trillium Health Partners, University of Toronto, Eye, Visual Science, CGS, American Society of Cataract and Refractive Surgery, International Society, ARVO, Scientific Committee on Emerging and Newly Identified Health Risks, Patient, Diagnosis, Medical device, Ophthalmology

DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.

Key Points: 
  • DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.
  • “We are truly honoured that Dr. Ahmed has agreed to join Hexiris Pharma’s Scientific Committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris Pharma.
  • I’m pleased to be joining the Scientific Committee at Hexiris Pharma and join in the important work of improving the lives of patients and bringing new solutions and opportunities to ophthalmologists,” said Dr. Ahmed.
  • He has given over 750 scientific presentations thus far in his career, including 31 visiting professor’s lectures around the world.

Prevent Blindness Declares August as Children's Eye Health and Safety Month to Help Educate Families on the Importance of Healthy Vision and Early Access to Eyecare

Retrieved on: 
Monday, July 31, 2023
Eye Health UK, Strabismus, University, NEI, Visual impairment, Illinois Eye and Ear Infirmary, Head, Parent, University of Illinois Chicago College of Dentistry, Family, Amblyopia, MBA, Vision, Visual Science, MSC, MD, National Eye Institute, University of Illinois Urbana-Champaign, FACS, Near-sightedness, Caregiver, Retinopathy, Ear, Social media, Management, Ophthalmology

CHICAGO, July 31, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading volunteer eye health and safety nonprofit organization, has declared August as Children's Eye Health and Safety Month in an effort to educate parents and caregivers on ways to keep children's eyes healthy. As many kids are headed back to school in the month of August, Prevent Blindness offers free resources including fact sheets and social media graphics in English and Spanish, toolkits, and webpages on a variety of topics, including myopia (nearsightedness), amblyopia (lazy eye), strabismus (crossed eyes), eye safety in relation to digital screen time, importance of vision screenings, financial assistance programs, and much more.

Key Points: 
  • Prevent Blindness Offers New Episode of its Focus on Eye Health Expert Series, Collaborative Episode of the BlackDoctor.org "Seeing Eye to Eye" Series, Resources for Families and Children for the Upcoming Solar Eclipses, and More.
  • CHICAGO, July 31, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading volunteer eye health and safety nonprofit organization, has declared August as Children's Eye Health and Safety Month in an effort to educate parents and caregivers on ways to keep children's eyes healthy.
  • Additionally, Prevent Blindness is debuting a new episode in the online Focus on Eye Health Expert Series, " Children's Vision and Eye Health ."
  • And, as part of the Focus on Eye Health Expert series, Michael F. Chiang, MD , Director of the National Eye Institute (NEI), recently spoke with Jeff Todd

Validation of a Novel Head-Mounted Perimeter versus the Humphrey Field Analyzer

Retrieved on: 
Friday, July 7, 2023
M&S, Glaucoma, Visual field test, Eye, University, HFA, Smart system, Visual impairment, University of Iowa, Paratriathlon, Visual Science, Patient, Field line, Disease, Medical imaging, Medical device, Ophthalmology

NILES, Ill., July 7, 2023 /PRNewswire-PRWeb/ -- Researchers at the University of Iowa Carver College of Medicine and the Department of Ophthalmology and Visual Sciences recently completed a pilot study showing that a virtual reality headset can be used to reliably diagnose and monitor visual field loss in glaucoma patients. This study paves the way for wider adoption of such headsets, which will not only make testing quicker and more comfortable, but also more accessible for patients with mobility issues. This in turn would mean better screening and early detection of glaucoma in vulnerable parts of the population.

Key Points: 
  • This in turn would mean better screening and early detection of glaucoma in vulnerable parts of the population.
  • The study was conducted by two University of Iowa researchers who compared performance of a Smart System Virtual Reality Perimeter (SSVR) from M&S Technologies with a more traditional testing device, the Humphrey Field Analyzer (HFA).
  • Contrastingly, the SSVR is a head-mounted device that many users are already familiar with through other contexts, such as gaming.
  • The M&S SSVR is commercially available for use in visual field testing as well as numerous functional tests.

New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks

Retrieved on: 
Saturday, June 17, 2023
Pharmaceutical, Optical, Health, Clinical Trials, ENDO, Endocrine Practice, P81, University, Prevalence, AE, Emeritus, TJ Smith Stakes, Graves' ophthalmopathy, Week, Tinnitus, FACP, Aes, AACE, Huber loss, Human, Medicine, Research, Science, Visual Science, Incidence, Teprotumumab, Data, Patient, Risk, Michigan Medicine, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, TED, Pharmaceutical industry, Ophthalmology

Decreased hearing, particularly at high frequencies, has been observed in people with Graves’ disease, but specific prevalence data among the population with TED is limited.

Key Points: 
  • Decreased hearing, particularly at high frequencies, has been observed in people with Graves’ disease, but specific prevalence data among the population with TED is limited.
  • An analysis presented at ENDO ( P81, TJ Smith ) assessed data on hearing-related medical claims among people with Graves’ disease, TED and those who received TEPEZZA treatment.
  • In clinical trials, hearing-related AEs with insulin-like growth factor-I receptor inhibitors have been reported.
  • We will continue to advance the science of Thyroid Eye Disease with the patient voice at the forefront of all we do.”

MarketGrader Welcomes FinTech and Software Entrepreneurs Rob Foregger and Jim MacIntyre as Strategic Partners

Retrieved on: 
Wednesday, April 19, 2023
BMO, Paul Ecke Ranch, Partnership, Richard von Foregger, Dow Jones, Fintech, Visual Science, Personal Capital, MacIntyre, SS, GARP, Growth, EBay Enterprise, CORAL, Fidelity, Commerce, Software, Cryptocurrency

CORAL GABLES, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- MarketGrader , a leader in smart beta investment solutions, is pleased to announce a new strategic partnership with Rob Foregger , Jim MacIntyre , and their tech accelerator, Product Lab.

Key Points: 
  • CORAL GABLES, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- MarketGrader , a leader in smart beta investment solutions, is pleased to announce a new strategic partnership with Rob Foregger , Jim MacIntyre , and their tech accelerator, Product Lab.
  • Foregger is a FinTech pioneer, co-founding enterprise digital advice company NextCapital, digital wealth management firm Personal Capital, and online bank everbank.com.
  • MacIntyre is a software and e-commerce entrepreneur, co-founding Visual Sciences and multiple other software companies.
  • As part of the partnership, Foregger and MacIntyre will join the Board of Directors, act in a strategic advisory capacity, and take a minority stake in MarketGrader, providing it the support of Product Lab.

iSTAR Medical initiates international STAR-VI trial for the use of MINIject in conjunction with cataract surgery

Retrieved on: 
Wednesday, March 15, 2023
Glaucoma, Cataract, Patient, IOP, STAR, University of Utah, Ocular hypertension, MIGS, Paratriathlon, Istar, Visual Science, Safety, University, Pharmaceutical industry, Ophthalmology

iSTAR Medical’s STAR-VI trial is a prospective, interventional, multi-center, single-arm study which seeks to implant a total of 30 patients at up to seven sites in Europe and in Central America.

Key Points: 
  • iSTAR Medical’s STAR-VI trial is a prospective, interventional, multi-center, single-arm study which seeks to implant a total of 30 patients at up to seven sites in Europe and in Central America.
  • Patients will be followed for two years after their cataract surgery and concurrent MINIject® implantation.
  • MINIject® is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device and is currently the only commercially available supraciliary MIGS implant.
  • We are committed to delivering our breakthrough eye care solutions to patients globally and look forward to reporting clinical data from this study in due course.”